Biohaven Past Earnings Performance
Past criteria checks 0/6
Biohaven's earnings have been declining at an average annual rate of -32.8%, while the Biotechs industry saw earnings growing at 19.7% annually.
Key information
-32.8%
Earnings growth rate
-10.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -194.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
Sep 23Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Jul 26Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
May 18We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate
Apr 06
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Mar 01Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
Feb 28Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
Dec 08Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Dec 04Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True
Sep 27Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
Aug 28Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Jul 22Biohaven: A Promising Investment In Innovative Neurological Therapies
Jun 14Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
Jun 06Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
Apr 06Biohaven's spinal muscular atrophy therapy gets FDA fast track status
Feb 21Biohaven Ltd: Assessing The Spinoff
Dec 07Biohaven Non-GAAP EPS of -$1.25
Nov 09Revenue & Expenses Breakdown
How Biohaven makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -747 | 80 | 701 |
| 31 Mar 24 | 0 | -517 | 76 | 466 |
| 31 Dec 23 | 0 | -408 | 63 | 373 |
| 30 Sep 23 | 0 | -465 | 97 | 370 |
| 30 Jun 23 | 0 | -431 | 120 | 229 |
| 31 Mar 23 | 0 | -544 | 126 | 327 |
| 31 Dec 22 | 0 | -570 | 131 | 333 |
| 30 Sep 22 | 0 | -421 | 64 | 342 |
| 30 Jun 22 | 0 | -407 | 57 | 336 |
| 31 Mar 22 | 0 | -257 | 47 | 205 |
| 31 Dec 21 | 0 | -214 | 37 | 181 |
Quality Earnings: BHVN is currently unprofitable.
Growing Profit Margin: BHVN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BHVN is unprofitable, and losses have increased over the past 5 years at a rate of 32.8% per year.
Accelerating Growth: Unable to compare BHVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BHVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: BHVN has a negative Return on Equity (-194.56%), as it is currently unprofitable.